The role of NR2F1 in modulating immunotherapy responses also warrants investigation, including whether NR2F1-high melanomas are more responsive to PD-1 or CTLA-4 blockade, or if NR2F1 influences T cell infiltration (5). Here, CTLA4 is linked to melanoma.